Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men

for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions

Research output: Contribution to journalArticle

Abstract

The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325

Original languageEnglish (US)
Pages (from-to)52-61
Number of pages10
JournalPapillomavirus Research
Volume7
DOIs
StatePublished - Jun 1 2019

Fingerprint

Vaccination
Vaccines
HIV
African Americans
Human papillomavirus 6
Papillomavirus Vaccines
Hispanic Americans
Sexual Behavior
Logistic Models
Smoking
Clinical Trials
Infection

Keywords

  • Adolescents
  • Clinical trials
  • HIV
  • Human papillomavirus
  • Men who have sex with men
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions (2019). Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Research, 7, 52-61. https://doi.org/10.1016/j.pvr.2019.01.002

Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. / for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions.

In: Papillomavirus Research, Vol. 7, 01.06.2019, p. 52-61.

Research output: Contribution to journalArticle

for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions 2019, 'Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men', Papillomavirus Research, vol. 7, pp. 52-61. https://doi.org/10.1016/j.pvr.2019.01.002
for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions. Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Research. 2019 Jun 1;7:52-61. https://doi.org/10.1016/j.pvr.2019.01.002
for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions. / Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. In: Papillomavirus Research. 2019 ; Vol. 7. pp. 52-61.
@article{63d0fb42508345059344a512a8479882,
title = "Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men",
abstract = "The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2{\%} were African-American, and 26.2{\%} were Hispanic; 93{\%} had anal, 40{\%} penile, and 6{\%} oral HPV. Among those with anogenital infection, 18{\%} had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95{\%} CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95{\%} CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95{\%} CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325",
keywords = "Adolescents, Clinical trials, HIV, Human papillomavirus, Men who have sex with men, Vaccine",
author = "{for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions} and Kahn, {Jessica A.} and Marvin Belzer and Xiaofei Chi and Jeannette Lee and Gaur, {Aditya H.} and Kenneth Mayer and Jaime Martinez and Futterman, {Donna C.} and Stier, {Elizabeth A.} and Paul, {Mary E.} and Chiao, {Elizabeth Y.} and Daniel Reirden and Goldstone, {Steven E.} and {Ortiz Martinez}, {Ana P.} and Cachay, {Edward R.} and Barroso, {Luis F.} and {Da Costa}, Maria and Wilson, {Craig M.} and Palefsky, {Joel M.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.pvr.2019.01.002",
language = "English (US)",
volume = "7",
pages = "52--61",
journal = "Papillomavirus Research",
issn = "2405-8521",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men

AU - for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions

AU - Kahn, Jessica A.

AU - Belzer, Marvin

AU - Chi, Xiaofei

AU - Lee, Jeannette

AU - Gaur, Aditya H.

AU - Mayer, Kenneth

AU - Martinez, Jaime

AU - Futterman, Donna C.

AU - Stier, Elizabeth A.

AU - Paul, Mary E.

AU - Chiao, Elizabeth Y.

AU - Reirden, Daniel

AU - Goldstone, Steven E.

AU - Ortiz Martinez, Ana P.

AU - Cachay, Edward R.

AU - Barroso, Luis F.

AU - Da Costa, Maria

AU - Wilson, Craig M.

AU - Palefsky, Joel M.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325

AB - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation. Clinical trial number: NCT01209325

KW - Adolescents

KW - Clinical trials

KW - HIV

KW - Human papillomavirus

KW - Men who have sex with men

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85060700418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060700418&partnerID=8YFLogxK

U2 - 10.1016/j.pvr.2019.01.002

DO - 10.1016/j.pvr.2019.01.002

M3 - Article

C2 - 30658128

AN - SCOPUS:85060700418

VL - 7

SP - 52

EP - 61

JO - Papillomavirus Research

JF - Papillomavirus Research

SN - 2405-8521

ER -